



AML Academy 2019
Study Alliance Leukemia / CELL
7th /8th November 2019 in Dresden, Germany



Location Steigenberger Hotel de Saxe
 Neumarkt 9, 01067 Dresden

Agenda

Thursday, 7th November 2019

	AML Academy	
	Diagnosis and Prognostication	Chair:
13:00-13:20	Flow MRD – any hope for standardization?	Bonin
13:20-13:40	NGS – replacement for cytogenetics and new standard for MRD monitoring?	Metzeler
13:40-14:00	ELN risk classification – time for revision?	Schliemann
	Allogeneic SCT – still the best we have?	Chair:
14:00-14:20	Conditioning – any hope for standardization?	Bacigalupo
14:20-14:40	Maintenance post allo SCT – exception or rule?	Schmid
14:40-15:00	What to do when it failed?	Blaise
	<i>Break</i>	
	New approvals and shifting paradigms	Chair:
15:15-15:35	Induction – time for new standards?	Russell
15:35-15:55	Consolidation and maintenance – the cytarabine debate and the role of new agents	Wierzbowska
15:55-16:30	Non-intensive treatment – really improving? 	DiNardo
	<i>Break</i>	
	The AML development pipeline – what's next?	Chair:
16:45-17:05	Antibodies and CARs: Will they ever reach routine care?	Subklewe
17:05-17:35	New targeted agents – hope or hype? 	Montesinos
17:35-18:05	Cytostatics and other non-targeted approaches	Recher
	<i>Break</i>	
18:15 – 19:00	Keynote Lecture: In 5 years from now, AML treatment will look like this	Burnett
20:00	Dinner	

Friday, 8th November 2019

9:00 – 10:30	Patient management in real (rough) life: A European perspective	Chair:
	Roundtable discussion on time to treatment, genetic work-up, inpatient/outpatient management and the use of new drugs	
	France	Recher
	Poland	Wierzbowska
	Spain	Montesinos
	UK	Russell
	Italy	Bacigalupo
	Netherlands	Janssen
	<i>End of AML academy and break</i>	
11:00-12:30	SAL-Studiengruppentreffen	
12:30-13:30	Lunch	
13:30-15:30	SAL-Studiengruppentreffen	